Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 12/20 | 0.55 |
| ▸ | PARP1 | P09874 | 2/20 | 0.50 |
| ▸ | TNKS | O95271 | 1/20 | 0.50 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.45 |
| ▸ | MMP10 | P09238 | 4/20 | 0.39 |
| ▸ | MMP8 | P22894 | 4/20 | 0.39 |
| ▸ | TYMS | P04818 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27683279 | 0.85 | PIN1 (0.43) | MMP13PARP1TNKSTNKS2PIN1 | |
| SCHEMBL8204538 | 0.81 | PARP1 (0.60) | MMP13PARP1TNKSTNKS2PIN1 | |
| SCHEMBL688942 | 0.79 | MMP13 (0.56) | MMP13PARP1TNKSTNKS2MMP10 | |
| SCHEMBL20339664 | 0.76 | PARP1 (0.57) | MMP13PARP1TNKSTNKS2 | |
| SCHEMBL29903044 | 0.76 | PARP1 (0.57) | MMP13PARP1TNKSTNKS2 | |
| SCHEMBL15840736 | 0.76 | PARP1 (0.66) | MMP13PARP1TNKSTNKS2TYMS | |
| SCHEMBL26018100 | 0.76 | PARP1 (0.50) | MMP13PARP1TNKSTNKS2TYMS | |
| SCHEMBL4937745 | 0.75 | MMP13 (0.74) | MMP13MMP10MMP8 | |
| SCHEMBL8198164 | 0.74 | PIN1 (0.44) | MMP13PIN1TYMS | |
| SCHEMBL8198412 | 0.73 | TUBB4A (0.52) | PARP1TNKSTNKS2PIN1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | GEGE CHRISTIAN | 2008-10-23 | — | — | US | disclosed |
| WO-2008063668-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261968-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | MMP13 1/4885PARP1 156/4885TNKS 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.